| Literature DB >> 17324256 |
Hua Zhu1, Yuhong Tang, Lacramioara Ivanciu, Michael Centola, Cristina Lupu, Fletcher B Taylor, Florea Lupu.
Abstract
BACKGROUND: Bacterial invasion during sepsis induces disregulated systemic responses that could lead to fatal lung failure. The purpose of this study was to relate the temporal dynamics of gene expression to the pathophysiological changes in the lung during the first and second stages of E. coli sepsis in baboons.Entities:
Mesh:
Year: 2007 PMID: 17324256 PMCID: PMC1819384 DOI: 10.1186/1471-2164-8-58
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Venn diagram of the differentially expressed genes in the . a: genes up-regulated; b: genes down-regulated at three time points.
Genes up-regulated by sepsis in the lung of the baboons at 2, 8 and 24 hr post E. coli challenge
| chemokine (C-X-C motif) ligand 2 (CXCL2) | 10.8 | |||
| chemokine (C-C motif) ligand 20 (CCL20) | 8.3 | |||
| interleukin 1, beta (IL1B) | 4.5 | |||
| chemokine (C-X-C motif) ligand 11 (CXCL11) | 4.4 | 10.5 | ||
| chemokine (C-X-C motif) ligand 10 (CXCL10) | 4.3 | |||
| chemokine (C-C motif) ligand 2 (CCL2) | 3.5 | |||
| interferon regulatory factor 1 (IRF1) | 3.0 | 3.8 | ||
| interleukin 6 (interferon, beta 2) (IL6) | 2.2 | |||
| interleukin 15 receptor, alpha (IL15RA) | 2.2 | |||
| chemokine (C-C motif) ligand 4 (CCL4) | 2.2 | |||
| colony stimulating factor 3 (granulocyte) (CSF3) | 4.4 | |||
| chemokine (C-C motif) ligand 3-like 1(CCL3L1) | 2.6 | 3.0 | 2.0 | |
| interleukin 1 receptor antagonist (IL1RN) | 2.8 | |||
| vascular cell adhesion molecule 1 (VCAM1) | 6.9 | 4.7 | ||
| intercellular adhesion molecule 1 (CD54), human rhinovirus receptor (ICAM1) | 3.5 | |||
| carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) | 2.0 | |||
| junctional adhesion molecule 2 (JAM2) | 2.0 | 2.3 | ||
| vasodilator-stimulated phosphoprotein (VASP) | 2.3 | 2.1 | ||
| C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5 | 2.01 | |||
| syndecan 4 (amphiglycan, ryudocan) (SDC4) | 6.0 | |||
| guanylate binding protein 2, interferon-inducible (GBP2) | 10.2 | 16.3 | 2.3 | |
| guanylate binding protein 1, interferon-inducible, 67 kDa (GBP1) | 3.8 | 4.5 | ||
| tumor necrosis factor, alpha-induced protein 2 (TNFAIP2) | 3.4 | |||
| TNFAIP3 interacting protein 1 (TNIP1) | 2.9 | |||
| tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) | 2.5 | |||
| receptor-interacting serine-threonine kinase 2 (RIPK2) | 2.1 | |||
| S100 calcium binding protein A8 (calgranulin A) (S100A8) | 12.0 | 27.5 | 6.2 | |
| S100 calcium binding protein A9 (calgranulin B) (S100A9) | 7.7 | 17.5 | ||
| CD160 antigen (CD160) | 2.2 | 2.0 | ||
| chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1) | 3.2 | 2.5 | ||
| lymphocyte antigen 86 (LY86) (MD-1) | 2.3 | |||
| serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 (SERPINA3) | 5.6 | 6.8 | ||
| proteasome (prosome, macropain) activator subunit 2 (PA28 beta) (PSME2) | 3.1 | |||
| proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7) (PSMB8) | 3.2 | |||
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) (HIF1A) | 2.9 | 2.5 | ||
| thioredoxin reductase 1 (TXNRD1) | 2.1 | |||
| superoxide dismutase 2, mitochondrial (SOD2) | 12.5 | 5.0 | ||
| Haptoglobin (HP) | 33.3 | 24.4 | ||
| baculoviral IAP repeat-containing 3 (BIRC3) | 2.9 | |||
| growth arrest and DNA-damage-inducible, beta (GADD45B) | 3.0 | |||
| proteoglycan 1, secretory granule (PRG1) | 2.3 | 2.4 | ||
| CARD only protein (COP) | 9.6 | 11.8 | ||
| pleckstrin homology-like domain, family A, member 2 (PHLDA2) | 3.1 | |||
| homeodomain interacting protein kinase 3 (HIPK3) | 2.0 | |||
| G-2 and S-phase expressed 1 (GTSE1) | 2.0 | |||
| mitogen-activated protein kinase 8 interacting protein 1 (MAPK8IP1) | 2.3 | |||
| heat shock 27 kDa protein 8 (HSPB8) | 3.0 | 2.7 | ||
| pleckstrin homology-like domain, family A, member 2 (PHLDA2) | 2.8 | |||
| neuromedin B (NMB) | 2.0 | |||
| murine retrovirus integration site 1 homolog (MRVI1) | 2.7 | |||
| cyclin-dependent kinase 8 (CDK8) | 2.7 | |||
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 (SMARCB1) | 2.4 | |||
| fibroblast activation protein, alpha (FAP) | 4.3 | |||
| tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (TIE) | 2.9 | |||
| mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT2) | 2.9 | |||
| fibroblast growth factor 23 (FGF23) | 2.3 | |||
| stromal antigen 2 (STAG2) | 2.3 | |||
| SA hypertension-associated homolog (rat) (SAH) | 2.3 | |||
| slit homolog 1 (Drosophila) (SLIT1) | 2.2 | |||
| carboxypeptidase N, polypeptide 2, 83 kD (CPN2) | 2.1 | |||
| fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) (FLT1) | 2.2 | 3.2 | ||
| PR domain containing 5 (PRDM5) | 2.0 | 2.5 | ||
| activin A receptor, type IB (ACVR1B) | 2.4 | |||
| coagulation factor III (thromboplastin, tissue factor) (F3) | 2.5 | |||
| response gene to complement 32 (RGC32) | 3.7 | |||
| natriuretic peptide precursor C (NPPC) | 2.8 | |||
| solute carrier family 25, member 28 (SLC25A28) | 2.1 | |||
| cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) | 3.5 | 3.4 | ||
| ATP-binding cassette, sub-family C (CFTR/MRP), member 5 (ABCC5) | 2.3 | |||
| nicotinamide nucleotide transhydrogenase (NNT) | 2.7 | |||
| guanine nucleotide binding protein (G protein), alpha 14 (GNA14) | 2.1 | |||
| glutamate-ammonia ligase (glutamine synthase) (GLUL) | 2.1 | |||
| tryptophanyl-tRNA synthetase (WARS) | 2.1 | 8.0 | 3.4 | |
| ribosomal protein S27a (RPS27A) | 2.1 | |||
| isoleucine-tRNA synthetase (IARS) | 2.0 | |||
| solute carrier family 30 (zinc transporter), member 6 (SLC30A6) | 2.0 | |||
| solute carrier family 39 (zinc transporter), member 8 (SLC39A8) | 4.4 | 3.6 | ||
| solute carrier family 39 (zinc transporter), member 14 (SLC39A14) | 2.2 | |||
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA) | 6.2 | |||
| YY1 transcription factor (YY1) | 2.6 | |||
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon (NFKBIE) | 2.4 | |||
| bromodomain adjacent to zinc finger domain, 1A (BAZ1A) | 2.0 | |||
| general transcription factor IIA, 1, 19/37 kDa (GTF2A1) | 2.1 | |||
| PRP4 pre-mRNA processing factor 4 homolog (yeast) (PRPF4) | 2.7 | |||
| homeo box A11 (HOXA11) | 2.1 | |||
| nuclear receptor coactivator 2 (NCOA2) | 3.5 | |||
| nuclear fragile × mental retardation protein interacting protein 1 (NUFIP1) | 3.4 | |||
| splicing factor, arginine/serine-rich 2, interacting protein (SFRS2IP) | 3.3 | |||
| forkhead box K2 (FOXK2) | 3.1 | |||
| I-mfa domain-containing protein (HIC) | 2.0 | |||
| nuclear receptor subfamily 2, group F, member 2 (NR2F2) | 2.0 | |||
| myristoylated alanine-rich protein kinase C substrate (MARCKS) | 3.0 | |||
| tubulin, beta, 4 (TUBB4) | 2.5 | 3.5 | ||
| RAP1A, member of RAS oncogene family (RAP1A) | 2.7 | |||
| apolipoprotein L, 1 (APOL1) | 3.7 | 12.4 | ||
| lipocalin 2 (oncogene 24p3) (LCN2) | 8.6 | 10.7 | ||
| lipase, gastric (LIPF) | 2.1 | |||
| like-glycosyltransferase (LARGE) | 2.3 | |||
| UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 (GalNAc-T13) | 2.0 | |||
| heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 (HS3ST3A1) | 2.1 | |||
| Heparanase (HPSE) | 2.1 | |||
| yrosine kinase with immunoglobulin and epidermal growth factor homology domains (TIE) | 2.9 | |||
| mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT2) | 2.9 | |||
| UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) | 3.3 | |||
| mitogen-activated protein kinase kinase kinase 3 (MAP3K3) | 3.0 | |||
| BMX non-receptor tyrosine kinase (BMX) | 2.6 | |||
| guanine nucleotide binding protein (G protein), alpha 14 (GNA14) | 2.1 | |||
| guanine nucleotide binding protein (G protein), beta polypeptide 3 (GNB3) | 2.6 | 2.2 | ||
| guanine nucleotide binding protein (G protein), beta 5 (GNB5) | 2.7 | |||
| guanine nucleotide binding protein (G protein), gamma 10 (GNG10) | 2.2 | 2.5 | ||
| G protein-coupled receptor 1 (GPR1) | 3.3 | |||
Genes downregulated by sepsis in the lung of the baboons at 2, 8 and 24 hrs post E. coli challenge
| 2 h | 6–8 h | 24 h | ||
| tumor necrosis factor receptor superfamily, member 8 (TNFRSF8) | 0.23 | 0.18 | ||
| alpha-2-macroglobulin (A2M) | 0.48 | |||
| chemokine (C-X-C motif) ligand 5 (CXCL5) | 0.50 | |||
| integrin beta 1 binding protein 1 (ITGB1BP1) | 0.50 | |||
| complement component 7 (C7) | 0.32 | |||
| major histocompatibility complex, class II, DR beta 3 (HLA-DRB3) | 0.33 | |||
| Caveolin 1 protein (CAV1) | 0.49 | |||
| Thrombomodulin (THBD) | 0.39 | 0.17 | 0.25 | |
| CD59 antigen p18–20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) (CD59) | 0.42 | |||
| alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase) (ANPEP) | 0.43 | |||
| matrix metalloproteinase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) (MMP2) | 0.36 | 0.36 | ||
| tissue inhibitor of metalloproteinase 2 (TIMP2) | 0.46 | 0.45 | ||
| collagen, type VI, alpha 1 (COL6A1) | 0.48 | |||
| collagen, type VI, alpha 3 (COL6A3) | 0.30 | |||
| tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3) | 0.32 | |||
| connective tissue growth factor (CTGF) | 0.37 | |||
| upregulated in colorectal cancer gene 1 (UCC1) | 0.40 | |||
| CD9 antigen (p24) (CD9) | 0.30 | |||
| fibronectin 1 (FN1) | 0.37 | |||
| plakophilin 4 (PKP4) | 0.44 | 0.43 | ||
| claudin 4 (CLDN4) | 0.46 | |||
| vascular endothelial growth factor (VEGF) | 0.40 | |||
| discoidin domain receptor family, member 1 (DDR1) | 0.44 | |||
| Vinculin (VCL) | 0.50 | |||
| delta sleep inducing peptide, immunoreactor (DSIPI) | 0.41 | 0.39 | ||
| dual specificity phosphatase 6 (DUSP6) | 0.45 | |||
| inhibitor of DNA binding 1, dominant negative helix-loop-helix protein (ID1) | 0.34 | |||
| transcription factor Dp-2 (E2F dimerization partner 2) (TFDP2) | 0.37 | |||
| keratin 19 (KRT19) | 0.35 | |||
| epithelial membrane protein 2 (EMP2) | 0.42 | 0.44 | ||
| erythrocyte membrane protein band 4.1-like 2 (EPB41L2) | 0.42 | |||
| retinoblastoma binding protein 4 (RBBP4) | 0.45 | 0.45 | ||
| cytoskeleton related vitamin A responsive protein (JWA) | 0.45 | |||
| cyclin-dependent kinase (CDC2-like) 11 (CDK11) | 0.45 | |||
| NDRG family member 2 (NDRG2) | 0.46 | |||
| carboxypeptidase M (CPM) | 0.47 | 0.47 | ||
| glypican 6 (GPC6) | 0.49 | |||
| cyclin I (CCNI) | 0.20 | |||
| serine/threonine kinase 38 like (STK38L) | 0.32 | 0.11 | ||
| H3 histone, family 3B (H3.3B) (H3F3B) | 0.22 | |||
| erythrocyte membrane protein band 4.1-like 2 (EPB41L2) | 0.25 | |||
| nuclear mitotic apparatus protein 1 (NUMA1) | 0.36 | |||
| insulin-like growth factor binding protein 7 (IGFBP7) | 0.37 | |||
| Epimorphin (EPIM) | 0.38 | |||
| thymosin, beta 4, X-linked (TMSB4X) | 0.40 | |||
| RNA binding motif protein 5 (RBM5) | 0.41 | |||
| transmembrane 4 superfamily member 13 (TM4SF13) | 0.41 | |||
| mortality factor 4 like 1 (MORF4L1) | 0.47 | |||
| chromodomain helicase DNA binding protein 2 (CHD2) | 0.38 | |||
| paired-like homeobox 2b (PHOX2B) | 0.41 | 0.43 | ||
| general transcription factor IIIC, polypeptide 4, 90 kDa (GTF3C4) | 0.41 | |||
| ring finger protein 4 (RNF4) | 0.44 | 0.28 | ||
| ras responsive element binding protein 1 (RREB1) | 0.49 | |||
| prefoldin 5 (PFDN5) | 0.32 | |||
| zinc finger protein 9 (a cellular retroviral nucleic acid binding protein) (ZNF9) | 0.34 | |||
| heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B1) | 0.36 | |||
| signal transducer and activator of transcription 4 (STAT4) | 0.38 | |||
| PHD finger protein 6 (PHF6) | 0.34 | 0.39 | ||
| v-jun sarcoma virus 17 oncogene homolog (avian) (JUN) | 0.40 | |||
| transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) (TCF12) | 0.43 | |||
| heterogeneous nuclear ribonucleoprotein C (C1/C2) (HNRPC) | 0.43 | |||
| core promoter element binding protein (COPEB) | 0.45 | |||
| TEA domain family member 1 (SV40 transcriptional enhancer factor) (TEAD1) | 0.45 | |||
| transforming growth factor beta-stimulated protein TSC-22 (TSC22) | 0.46 | |||
| general transcription factor IIIC, polypeptide 4, 90 kDa (GTF3C4) | 0.50 | |||
| glutathione peroxidase 1 (GPX1) | 0.30 | |||
| apolipoprotein E (APOE) | 0.36 | |||
| death-associated protein (DAP) | 0.40 | |||
| glutathione S-transferase M5 (GSTM5) | 0.45 | |||
| protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform (PPM1A) | 0.48 | |||
| solute carrier family 2 (facilitated glucose transporter), member 9 (SLC2A9) | 0.42 | |||
| cytochrome b reductase 1 (CYBRD1) | 0.42 | |||
| indoleamine-pyrrole 2,3 dioxygenase (INDO) | 0.44 | 0.29 | ||
| ribosomal protein L22 (RPL22) | 0.49 | |||
| solute carrier family 30 (zinc transporter), member 1 (SLC30A1) | 0.49 | |||
| ribosomal protein L7 (RPL7) | 0.22 | |||
| ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D (ATP6V1D) | 0.31 | |||
| ribosomal protein S6 (RPS6) | 0.32 | |||
| cytochrome c oxidase subunit VIIc (COX7C) | 0.35 | |||
| solute carrier family 2 (facilitated glucose transporter), member 9 (SLC2A9) | 0.38 | |||
| eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2) | 0.42 | |||
| eukaryotic translation elongation factor 2 (EEF2) | 0.43 | |||
| eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2) | 0.43 | |||
| eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67 kDa (EIF3S7) | 0.43 | |||
| flavin containing monooxygenase 2 (FMO2) | 0.45 | |||
| solute carrier family 25 (mitochondrial carrier* phosphate carrier), member 3 (SLC25A3) | 0.46 | |||
| dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT) | 0.48 | |||
| eukaryotic translation initiation factor 3, subunit 6 interacting protein (EIF3S6IP) | 0.50 | |||
| matrix Gla protein (MGP) | 0.25 | 0.19 | ||
| adaptor-related protein complex 2, beta 1 subunit (AP2B1) | 0.38 | |||
| RAB36, member RAS oncogene family (RAB36) | 0.40 | |||
| RAB2, member RAS oncogene family (RAB2) | 0.34 | |||
| RAB6A, member RAS oncogene family (RAB6A) | 0.25 | |||
| sortilin 1 (SORT1) | 0.47 | |||
Oligonucleotide sequences of the primers used for QRT-PCR
| BIRC3 | F 5'-GTG ATG GTG GAC TCA GGT GTT G-3' | |
| COP1 | F 5'-CAG GCA GTG CGA GGA CAA-3' | |
| HIF1A | F 5'-CCA AAT CCA GAG TCA CTG GAA CTT-3' | |
| RIPK2 | F 5'-ACG TCT GCA GCC TGG TAT AGC-3' | |
| S100A8 | F 5'-CAA GTC CGT GGG CAT CAT G-3' | |
| SDC4 | F 5'-GGC AAG AAA CCC ATC TAC AAG AA-3' | |
| TNFAIP3 | F 5'-CTG CCC AGG AAT GCT ACA GAT AC-3' | |
| CAV1 | F 5'-ACA CCG TCT GTG ACC CAC TCT-3' | |
| THBD | F 5'-CCA GCT CTA CTG GTC TTG TGG AA-3' | |
| β-actin | F 5'-AAG CCA CCC CAC TTC TCT CTA A-3' |
Abbreviations: F, forward; R, reverse.
Gene expression validation using QRT-PCR
| TNFAIP3 | 9.64 | 23.66 | 17.60 | 10.87 | 1 | 8.77 | 4.63 | 151 | 0.995 |
| BIRC3 | 7.77 | 22.24 | 14.76 | 7.23 | 1 | 3.79 | 2.52 | 1.27 | 0.993 |
| RIPK2 | 6.73 | 14.17 | 10.43 | 8.34 | 1 | 9.48 | 5.65 | 1.24 | 0.978 |
| SDC4 | 4.27 | 25.44 | 6.77 | 7.91 | 1 | 4.23 | 1.59 | 0.84 | 0.967 |
| THBD | 28.10 | 11.15 | 4.97 | 7.09 | 1 | 0.3 | 0.33 | 0.21 | 0.958 |
| CAV1 | 13.31 | 6.65 | 7.15 | 3.44 | 1 | 0.64 | 0.51 | 0.61 | 0.843 |
| COP | 1.38 | 13.28 | 16.27 | 2.94 | 1 | 1.19 | 3.85 | 0.18 | 0.782 |
| S100A8 | 9.29 | 111.85 | 255.40 | 57.64 | 1 | 9.41 | 8.77 | 4.96 | 0.779 |
| HIF1A | 6.17 | 17.79 | 15.62 | 7.77 | 1 | 2.13 | 6.66 | 1.13 | 0.602 |
Figure 2Ward's hierarchical cluster analysis of time-dependent gene expression patterns in the lungs of . a: Differentially expressed genes were used in the hierarchical clustering analysis by Spotfire DecisionSite 8.1 (Spotfire, Sommerville, MA). Wards's method computes cluster proximity by the squared Euclidean distance between the gene cluster mean profiles. With this method ten clusters of genes with similar profiles were generated. See the Additional file 1 for a list of genes grouped in each cluster. b: Heat map of hierarchical clustering analysis. The hierarchical clustering process is represented as a tree, or dendrogram, where each step in the clustering process is illustrated by a join of the tree. Red color indicates a Z-score 1, green color indicates a Z-score equal to -1. The colors between red and green indicate Z-scores between 1 and -1.
Figure 3Ingenuity Pathway Analysis (IPA) of the differentially expressed genes at different time points after . Green indicates down-regulation and red indicates up-regulation. In this map all genes shown were statistically different from the control. A line indicates that two gene products show binding, a line terminated by arrow indicate that one gene product acts on the other gene product, and the plus sign indicate that other networks contain the gene product. The networks with the highest score in each time-point group are illustrated. a: IPA network 1 at 2 hrs; b: IPA network 1 at 8 hrs; c: IPA network 1 at 24 hrs. See the Additional files 2, 3, 4 for lists of genes involved in each network.
Figure 4Cytokine quantitation in lung extracts and plasma of . TNF-α, IL-1β, IL-4, IL-6, IL-8, IL-10 and G-CSF were assayed in lung lysates and plasma using a multiplex assay, as described in the Methods section. The values represent calculated as ratio per total protein in cell lysates or per ml of plasma, and presented as mean ± SD (n = 3). Asterisks (*) indicate p < 0.05 t-test values for lung and plasma samples of challenged animals (2, 8 and 24 hrs post E. coli infusion) vs. non-challenged controls.
Figure 5Electron microscopy analysis of structure changes in . a: normal architecture of the alveolar septae in healthy baboons; b. accumulation of neutrophils (PMN) and the presence of intra-alveolar bleeding erythrocytes (arrow) can be observed at 2 hrs; c: the increased accumulation of macrophages, fibroblasts and collagen deposition at 24 hrs. av, alveola; coll, collagen; Fb, fibroblasts; Mac, macrophages; RBC, red blood cells. Magnification: ×7000.